Chikungunya Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Chikungunya Pipeline Analysis report covers drugs of 11 companies currently in different phases of development. Chikungunya is a viral disease caused by a virus-infected mosquito to humans. Major symptoms include fever and severe joint pains and the other symptoms include a headache, nausea, fatigue, and rash among others. Currently, there is no anti-viral drug treatment for chikungunya and no commercial vaccine till date.
The report provides Chikungunya treatment drugs by companies, phases of development including products in the early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Bharat Biotech, PaxVax, Inc., Inovio Pharmaceuticals, Inc. and Globavir, Inc. among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
.jpg)
